Literature DB >> 10482566

Bovine leukemia virus structural gene vectors are immunogenic and lack pathogenicity in a rabbit model.

L Kucerova1, V Altanerova, C Altaner, K Boris-Lawrie.   

Abstract

Infection with a replication-competent bovine leukemia virus structural gene vector (BLV SGV) is an innovative vaccination approach to prevent disease by complex retroviruses. Previously we developed BLV SGV that constitutively expresses BLV gag, pol, and env and related cis-acting sequences but lacks tax, rex, RIII, and GIV and most of the BLV long terminal repeat sequences, including the cis-acting Tax and Rex response elements. The novel SGV virus is replication competent and replicates a selectable vector to a titer similar to that of the parental BLV in cell culture. The overall goal of this study was to test the hypothesis that infection with BLV SGV is nonpathogenic in rabbits. BLV infection of rabbits by inoculation of cell-free BLV or cell-associated BLV typically causes an immunodeficiency-like syndrome and death by 1 year postinfection. We sought to evaluate whether in vivo transfection of BLV provirus recapitulates pathogenic BLV infection and to compare BLV and BLV SGV with respect to infection, immunogenicity, and clinical outcome. Three groups of rabbits were subjected to in vivo transfection with BLV, BLV SGV, or negative control DNA. The results of our 20-month study indicate that in vivo transfection of rabbits with BLV recapitulates the fatal BLV infection produced by cell-free or cell-associated BLV. The BLV-infected rabbits exhibited sudden onset of clinical decline and immunodeficiency-like symptoms that culminated in death. BLV and BLV SGV infected peripheral blood mononuclear cells and induced similar levels of seroconversion to BLV structural proteins. However, BLV SGV exhibited a reduced proviral load and did not trigger the immunodeficiency-like syndrome. These results are consistent with the hypothesis that BLV SGV is infectious and immunogenic and lacks BLV pathogenicity in rabbits, and they support the use of this modified proviral vector delivery system for vaccines against complex retroviruses like BLV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482566      PMCID: PMC112833          DOI: 10.1128/JVI.73.10.8160-8166.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge.

Authors:  A D Hislop; M F Good; L Mateo; J Gardner; M H Gatei; R C Daniel; B V Meyers; M F Lavin; A Suhrbier
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

2.  The 5' RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production.

Authors:  M Butsch; S Hull; Y Wang; T M Roberts; K Boris-Lawrie
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

4.  Infection of rats with bovine leukaemia virus: establishment of a virus-producing rat cell line.

Authors:  V Altanerova; D Portetelle; R Kettmann; C Altaner
Journal:  J Gen Virol       Date:  1989-07       Impact factor: 3.891

5.  Evidence for the replication of bovine leukemia virus in the B lymphocytes.

Authors:  P S Paul; K A Pomeroy; D W Johnson; C C Muscoplat; B S Handwerger; F F Soper; D K Sorensen
Journal:  Am J Vet Res       Date:  1977-06       Impact factor: 1.156

6.  Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.

Authors:  N D Collins; G C Newbound; B Albrecht; J L Beard; L Ratner; M D Lairmore
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

7.  Experimental transmission of enzootic bovine leukosis to sheep: latency period of the tumoral disease.

Authors:  M Mammerickx; R Palm; D Portetelle; A Burny
Journal:  Leukemia       Date:  1988-02       Impact factor: 11.528

8.  trans-acting regulation of bovine leukemia virus mRNA processing.

Authors:  D Derse
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

Review 9.  Bovine leukaemia: facts and hypotheses derived from the study of an infectious cancer.

Authors:  A Burny; Y Cleuter; R Kettmann; M Mammerickx; G Marbaix; D Portetelle; A Van den Broeke; L Willems; R Thomas
Journal:  Cancer Surv       Date:  1987

10.  The bovine leukemia virus p34 is a transactivator protein.

Authors:  L Willems; A Gegonne; G Chen; A Burny; R Kettmann; J Ghysdael
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  8 in total

1.  Discordance between bovine leukemia virus tax immortalization in vitro and oncogenicity in vivo.

Authors:  J C Twizere; P Kerkhofs; A Burny; D Portetelle; R Kettmann; L Willems
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits.

Authors:  Veronika Altanerova; Dana Holicova; Lucia Kucerova; Cestmir Altaner; Michael D Lairmore; Kathleen Boris-Lawrie
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

Review 3.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

Review 4.  Vaccination against δ-retroviruses: the bovine leukemia virus paradigm.

Authors:  Gerónimo Gutiérrez; Sabrina M Rodríguez; Alix de Brogniez; Nicolas Gillet; Ramarao Golime; Arsène Burny; Juan-Pablo Jaworski; Irene Alvarez; Lucas Vagnoni; Karina Trono; Luc Willems
Journal:  Viruses       Date:  2014-06-20       Impact factor: 5.048

5.  Identification of conserved, primary sequence motifs that direct retrovirus RNA fate.

Authors:  Gatikrushna Singh; Brittany D Rife; Bradley Seufzer; Marco Salemi; Aaron Rendahl; Kathleen Boris-Lawrie
Journal:  Nucleic Acids Res       Date:  2018-08-21       Impact factor: 16.971

6.  Dairy Cows Experimentally Infected With Bovine Leukemia Virus Showed an Increased Milk Production in Lactation Numbers 3-4: A 4-Year Longitudinal Study.

Authors:  Yi Yang; Zaicheng Gong; Yi Lu; Xubin Lu; Jilei Zhang; Ye Meng; Yalan Peng; Shuangfeng Chu; Wenqiang Cao; Xiaoli Hao; Jie Sun; Heng Wang; Aijian Qin; Chengming Wang; Shaobin Shang; Zhangping Yang
Journal:  Front Microbiol       Date:  2022-07-11       Impact factor: 6.064

7.  Animal models on HTLV-1 and related viruses: what did we learn?

Authors:  Hiba El Hajj; Rihab Nasr; Youmna Kfoury; Zeina Dassouki; Roudaina Nasser; Ghada Kchour; Olivier Hermine; Hugues de Thé; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2012-09-21       Impact factor: 5.640

Review 8.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.